Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.53 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.52 |
| ▸ | LOX | P28300 | 1/20 | 0.52 |
| ▸ | DAO | P14920 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | TKT | P29401 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40545 | 1.00 | LOXL2 (0.53) | LOXL2TRPV4LOXDAOMAOB | |
| Hydrochloric Acid SCHEMBL3494124 | 0.98 | LOXL2 (0.55) | LOXL2TRPV4LOXDAOMAOB | |
| SCHEMBL8190374 | 0.84 | LOXL2 (0.42) | LOXL2TRPV4LOXDAOMAOB | |
| SCHEMBL264730 | 0.84 | TAAR1 (0.52) | LOXL2TRPV4LOXDAOMAOB | |
| SCHEMBL24400400 | 0.83 | LOXL2 (0.40) | LOXL2TRPV4LOXDAOMAOB | |
| SCHEMBL30641637 | 0.83 | LOXL2 (0.40) | LOXL2TRPV4LOXDAOMAOB | |
| SCHEMBL5657097 | 0.81 | DAO (0.48) | LOXL2TRPV4LOXDAOMAOB | |
| SCHEMBL4375266 | 0.81 | ST14 (0.50) | LOXL2TRPV4LOXMAOB | |
| SCHEMBL21503682 | 0.79 | LOXL2 (0.40) | LOXL2TRPV4LOXDAOMAOB | |
| SCHEMBL317731 | 0.79 | TRPV4 (0.52) | LOXL2TRPV4LOXDAOMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025021943-A1 | QUINAZOLINONE, BENZOXAZINONE AND BENZOXAZEPINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NEURALIS (BE) | 2025-01-30 | — | — | WO | disclosed |
| CN-114025755-B | Therapeutic use of heterocyclic compounds as kinase inhibitors | 台湾卫生研究院 | 2024-11-29 | — | — | CN | disclosed |
| CN-114181205-B | Pyrazolopyridine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INT (DE) | 2023-11-09 | — | — | US | disclosed |
| CN-116981665-A | Novel compounds | 思瑞万斯公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11766443-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-26 | — | — | US | disclosed |
| CN-116789670-A | Selective CSF1R inhibitor and application thereof | 中国科学院合肥物质科学研究院 | 2023-09-22 | — | — | CN | disclosed |
| CN-111601798-B | Bisamide sarcomere activating compounds and uses thereof | 美国安进公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-110944670-B | Formulations of compounds for modulating kinases | 普莱希科公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-3747866-B1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | INST MATERIA MEDICA CAMS (CN) | 2023-03-01 | — | — | EP | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| CN-114668761-A | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20220160725-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2022-05-26 | — | — | US | disclosed |
| CN-108290878-B | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-114181205-A | Pyrazolopyridine compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-114127050-A | Benzopyran and imidazole derivatives useful for stabilizing amyloidogenic immunoglobulin light chains | 斯克利普斯研究所 | 2022-03-01 | — | — | CN | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160725-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, F3 | LOXL2 4341/4885TRPV4 517/4885LOX 4677/4885 |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | LOXL2 3954/4885TRPV4 242/4885LOX 4292/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | LOXL2 3954/4885TRPV4 242/4885LOX 4292/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | LOXL2 3954/4885TRPV4 242/4885LOX 4292/4885 |
| US-11766443-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | PTAFR, PDGFRA, F3 | LOXL2 4341/4885TRPV4 517/4885LOX 4677/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | LOXL2 3954/4885TRPV4 242/4885LOX 4292/4885 |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, F3 | LOXL2 4341/4885TRPV4 517/4885LOX 4677/4885 |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | LOXL2 3954/4885TRPV4 242/4885LOX 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.